The DOI matches its Crossref record.
Relaxin: Exploring the antifibrotic potential of a pregnancy hormone
Open accessAbstract
Excess accumulation of extracellular matrix proteins has been well recognized as a key feature of chronic kidney diseases. Renal fibrosis, particularly tubulointerstitial fibrosis, parallels the progressive loss of organ function, which ultimately leads to overt renal failure and the need for dialysis. Driven by distinct causes like hypertension, chronic inflammation, elevated blood glucose, or postrenal obstruction, development of kidney fibrosis is mediated and fine-tuned by a variety of cytokines, growth factors, and soluble factors. Among others, transforming growth factor-beta (TGF-b) is of pivotal importance because of its ability to regulate both matrix protein synthesis and degradation in a distinctive profibrotic manner. As the knowledge about TGF-b and matrix protein biology and pathophysiology has substantially increased over the recent years, new strategies to tackle renal fibrosis have been developed that are centered around the cascade of TGF-b generation, TGF-b signaling, and matrix protein deposition and degradation. An emerging novel therapeutic approach to target fibrosis is relaxin, a small peptide hormone that is endogenously produced by corpus luteum of the ovary. The name relaxin is derived from its unique ability to soften connective tissue of the reproductive tract in pregnancy (i.e., to relax the cervix and the pubic ligament to facilitate delivery) [1]. Relaxin has received additional interest because it mediates the profound vascular effects seen in pregnancy, too. The general hemodynamic changes and, especially, the changes in renal hemodynamics in pregnancy (decline in renal vascular resistance, increase in renal plasma flow and GFR) are mediated in large parts by relaxin through actions on nitric oxide and endothelin receptor B activation [1, 2]. Of particular interest to nephrologists, relaxin blocks the renal hemodynamic effects of angiotensin II independently of pregnancy [3]. These vascular effects appear largely dependent on the activation of matrix-metalloproteases (MMP), enzymes that digest and remove collagens and other matrix proteins [1, 2, 4]. Activation of MMPs by relaxin has been
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K.-U., Kasiske, B. L., McCullough, P. A., Passman, R. S., et al. (2011) · Kidney International · doi:10.1038/ki.2011.223 · Cited by 922
Bradbury, B. D., Fissell, R. B., Albert, J. M., Anthony, M. S., Critchlow, C. W., Pisoni, R. L., Port, F. K., & Gillespie, B. W. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01170905 · Cited by 492
NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Sudden Cardiac Death and Dialysis Patients
Herzog, C. A., Mangrum, J. M., & Passman, R. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00455.x · Cited by 290
Turakhia, M. P., Blankestijn, P. J., Carrero, J.-J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., Passman, R. S., Pecoits-Filho, R., Reinecke, H., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy060 · Cited by 288
Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics
Pun, P. H., Lehrich, R. W., Honeycutt, E. F., Herzog, C. A., & Middleton, J. P. (2011) · Kidney International · doi:10.1038/ki.2010.315 · Cited by 277
Metadata
- Authors
- Gaedeke, J., & Peters, H.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 68
- Issue
- 1
- Pages
- 405-406
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1512015690
- Cited by
- 179
- References
- 0
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relaxin: Exploring the antifibrotic potential of a pregnancy hormone. https://app.cochat.ai/papers/10.1111/j.1523-1755.2005.00462.x
- The paper
- Gaedeke, J., & Peters, H. (2005). Relaxin: Exploring the antifibrotic potential of a pregnancy hormone. Kidney International. https://doi.org/10.1111/j.1523-1755.2005.00462.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.